News

Prestige Brands launches Goody’s in shot format

BY Michael Johnsen

TARRYTOWN, N.Y. — Prestige Brands on Monday announced the launch of Goody’s Headache Relief Shot. The product combines the pain relievers acetaminophen and caffeine in a fast-acting, single-dose liquid. 

"We believe the Goody’s Headache Relief Shot is truly a game-changer in pain relief," stated Joseph Juliano, brand director, Goody’s. "There is no other product like it on the market. It contains proven ingredients that we know are effective in reducing pain and delivers them in a quick, easy-to-drink shot. One dose of this fast-action liquid and you can stop worrying about a headache and be on the go again."

NASCAR driver Dale Earnhardt Jr. will play a major role in the Goody’s Headache Relief Shot marketing campaign, including appearing in advertising, social media and retail promotions. The product will be sold at major retailers throughout the Southeast and nationally at Walmart, Walgreens and Dollar General. 

The Goody’s Headache Relief Shot will be sold in packages of two, with each 2 oz. bottle containing 1,000 mg of acetaminophen and 65 mg of caffeine, the company reported. It comes in citrus and berry flavors.

The product was recently showcased at the GMDC and FMI joint Health & Wellness @Retail 2013 conference, where it was selected by DSN editors as a "hot product." 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Cutex products now available at extreme-value retailer Five Below

BY Antoinette Alexander

ST. LOUIS — Cutex has announced the availability of its Advanced Revival formula at Five Below retail stores across the United States.

As the retail store’s name suggests, Five Below is offering select Cutex products for less than $5. Nail polish remover products include the Advanced Revival One-Step Remover Pads, Advanced Revival Liquid Nail Polish Remover, the Cutex Corrector Pen and Cutex Regular Instant Nail Polish Remover Jar.

“Cutex always looks for innovative ways to reach a new loyal customer base, and partnering with Five Below is a great way to get Cutex products into and onto the hands of many consumers around the nation,” stated John Mandelker, president of Cutex. “We take pride in our 100-year legacy allowing us to break ground in the innovation of new and better products.”

The Cutex Advanced Revival formula is the first innovation in nail polish remover in more than 15 years. The patent-pending formula combines the power of acetone with strengthening and nourishing natural apricot seed and parilla drying oils, the company stated.

Cutex Advanced Revival Nail Polish Remover Pads use the same Advanced Revival formula but are able to condition nails and cuticles in one step. The patented formula is designed to remove polish faster and create an ideal canvas for a base coat or nail polish that follows. Each felt pad is individually wrapped and removes polish from 10 nails, fingers or toes.

Also available at Five Below are the Cutex Corrector Pen and the Cutex Regular Instant Nail Polish Remover Jar. The Corrector Pen combines the performance of Cutex nail polish remover with the precision of a contoured applicator tip for quick, accurate touch-ups. The pen includes four extra tips in a portable design. The Cutex Regular Instant Nail Polish Remover Jar is an alternative to liquid polish removers. Each nail is cleaned by twisting one finger at a time with the sponge in the jar.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

AstraZeneca to buy developer of COPD drug

BY Alaric DeArment

LONDON — Anglo-Swedish drug maker AstraZeneca will pay up to $1.15 billion for a U.S. developer of drugs for respiratory diseases, AstraZeneca said Monday.

The company announced that it would buy Redwood City, Calif.-based Pearl Therapeutics, which has an inhaled drug for chronic obstructive pulmonary disease, called PT003 (formoterol fumarate; glycopyrrolate), in late-stage clinical development.

Under the deal, AstraZeneca will buy 100% of shares in Pearl, including a $560 million initial payment, up to $450 million in development-related milestone payments and $140 million in payments related to potential product sales. The deal is expected to close in the summer.

"Chronic obstructive pulmonary disease continues to increase worldwide, and there is a growing need for the next generation of inhaled combination products," AstraZeneca CEO Pascal Soriot said. "Pearl’s novel formulation technology, together with its development products and specialist expertise, is a great complement to AstraZeneca’s long-established capabilities in respiratory disease, one of our core therapy areas."

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES